Leading a pioneering approach
in antidepressant therapy
Depression is a disease that can strike anyone, at any age.
Mental health disorders can impact anyone. They are a universal concern.
people are now living
with depression worldwide,
including
in antidepressant therapy
Depression is a disease that can strike anyone, at any age.
Mental health disorders can impact anyone. They are a universal concern.
people are now living
with depression worldwide,
including
Total raised: $12.59M
Investors 2
| Date | Name | Website |
| 06.09.2025 | Capital Gr... | capitalgra... |
| 10.07.2026 | Kurma Part... | kurmapartn... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 11.06.2025 | Seed | $12.59M | - |
Mentions in press and media 3
| Date | Title | Description |
| 23.04.2026 | Kurma closes €215M Europe-focused fund to spread across 20 biotechs | Kurma Partners has closed its fourth biotech venture capital fund after raising 215 million euros ($252 million) to support European startups. Paris-based Kurma held the first close of Biofund IV in October 2024. At that time, the VC group ... |
| 11.06.2025 | Elkedonia Closes EUR 11M in Seed Funding | Elkedonia, a Strasbourg, France-based company leveraging a new neuroplastogen approach to develop therapeutic agents to treat depression and other neuropsychiatric condition, raised EUR 11M in Seed funding. The round was led by Kurma Partne... |
| - | Elkedonia | “Elkedonia - Elkedonia” |